Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma

BACKGROUND: Immune checkpoint inhibitor (ICI)-combined chemotherapy in advanced intrahepatic cholangiocarcinoma has been proved to have more efficacy in a series of clinical trials. However, whether the tumor microenvironment (TME) plays a vital role in immune-combined therapy has not been rigorousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Tian-mei, Pan, Yu-fei, Yuan, Zhen-gang, Chen, Dong-sheng, Song, Yun-jie, Gao, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501891/
https://www.ncbi.nlm.nih.gov/pubmed/36159865
http://dx.doi.org/10.3389/fimmu.2022.943066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501891/
https://www.ncbi.nlm.nih.gov/pubmed/36159865
http://dx.doi.org/10.3389/fimmu.2022.943066

Ejemplares similares